Drug Profile
TR 004
Alternative Names: TR-004; Treg immunotherapyLatest Information Update: 09 Feb 2023
Price :
$50
*
At a glance
- Originator Miltenyi Biotec GmbH
- Class Cell therapies; Regulatory T lymphocyte cell therapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Crohn's disease
Most Recent Events
- 08 Aug 2022 Phase-I clinical trials in Crohn's disease (Treatment-experienced) in United Kingdom (IV) (NCT03185000)
- 28 May 2021 No recent reports of development identified for preclinical development in Crohn's-disease in Germany (IV, Infusion)
- 13 Apr 2017 Miltenyl Biotech, in collaboration with Kings College London, plans the phase I TRIBUTE trial for Crohn's disease (In adults, In the elderly) in February 2018 (NCT03185000)